Revolutionizing Pharmaceutical Development: Pegasus Biotech Inc.’s BPE Plasmid Technology Takes the Lead
Pegasus Biotech Inc. is a full-service biotechnology contract research organization that specializes in vaccine and biopharmaceutical development. They have redesigned how plasmid DNA replicates, allowing for the control of when and how DNA is produced. This technology, known as BPE plasmid technology, uses a patented origin that can lay dormant during fermentation and trigger replication at high cell densities, resulting in significantly higher replication levels compared to existing technology. Additionally, the technology does not use an antibiotic resistance selection marker and contains minimal bacterial sequences, less than 1,000 base pairs.
This innovative technology offers enhanced expression, with cells transfected with BPE plasmid showing up to 7 times more expression than conventional plasmid backbones. The transformational nature of this technology is especially important in applications where cost of goods sold and patient safety are important factors. Daniel Wilson, the COO of Pegasus Biotech, emphasized the potential of this technology to facilitate the development and market entry of innovative biopharmaceutical and vaccine products.
Pegasus Biotech aims to ensure that client projects comply with global regulations and result in commercially viable products. Their services include seed-to-formulation process development and associated analytical development. For more information on Pegasus’ services, visit their website.
The project required low cost, minimal bacterial sequences, high expression, and no antibiotic resistance selection marker – all characteristics of this technology. Pegasus Biotech has developed a unique approach to plasmid DNA replication that allows for precise control over when and how DNA is produced. This new approach has significant implications for the development of biopharmaceuticals and vaccines in the global pharmaceutical industry.
